Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

G. Zheng, K. Sundquist, J. Sundquist, A. Försti, A. Hemminki, K. Hemminki

. 2020 ; 9 (21) : 8258-8265. [pub] 20200922

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019860

BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990-2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC-SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non-Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019860
003      
CZ-PrNML
005      
20210830101447.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.3454 $2 doi
035    __
$a (PubMed)32960498
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zheng, Guoqiao $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden
245    10
$a Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor / $c G. Zheng, K. Sundquist, J. Sundquist, A. Försti, A. Hemminki, K. Hemminki
520    9_
$a BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990-2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC-SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non-Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresivní léčba $7 D007165
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a sekundární malignity $x epidemiologie $x imunologie $7 D016609
650    _2
$a registrace $7 D012042
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Švédsko $x epidemiologie $7 D013548
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sundquist, Kristina $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Sundquist, Jan $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA $u Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 9, č. 21 (2020), s. 8258-8265
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32960498 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101447 $b ABA008
999    __
$a ok $b bmc $g 1690626 $s 1140306
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 21 $d 8258-8265 $e 20200922 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options